On Wednesday, Smith & Nephew ADR hit an important technical benchmark, with its Relative Strength (RS) Rating rising into the 80-plus percentile with an upgrade to 88, an increase from 75 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique rating measures price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they begin their biggest runs.
Smith & Nephew ADR is now considered extended and out of buy range after clearing a 31.72 buy point in a first-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Smith & Nephew ADR showed -2% earnings growth in the latest quarterly report, while sales growth came in at 5%.
The company earns the No. 12 rank among its peers in the Medical-Products industry group. TransMedics Group, Hinge Health and Boston Scientific are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
